Edition:
India

Regeneron Announces Positive Early-Stage Data For REGN1979 In Patients With B-Cell Non-Hodgkin Lymphoma


Friday, 14 Jun 2019 

June 14 (Reuters) - Regeneron Pharmaceuticals Inc ::REGENERON CD20XCD3 BISPECIFIC REGN1979 SHOWS POSITIVE RESULTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, INCLUDING IN CAR-T FAILURES.REGENERON PHARMACEUTICALS - IN THIS TRIAL, TWO PATIENTS WHO FAILED CAR-T THERAPY AND RECEIVED REGN1979 80 MG ACHIEVED COMPLETE RESPONSES.REGENERON PHARMACEUTICALS - 93% OVERALL RESPONSE & 71% COMPLETE RESPONSE RATES IN FOLLICULAR LYMPHOMA GRADES 1 TO 3A TREATED WITH REGN1979 5 MG-320 MG. 

Company Quote

82.68
0.23 +0.28%
16 Oct 2019